Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
TRIFERIC (ferric pyrophosphate citrate) is an intravenous iron replacement therapy administered as a powder formulation for reconstitution. It is indicated for iron replacement in patients with iron deficiency anemia, particularly those with chronic kidney disease on hemodialysis. The drug delivers bioavailable iron via a stable citrate-pyrophosphate complex.
Product is in peak revenue phase with high competitive pressure (8/10), suggesting stable commercial operations but intense promotional activity and team engagement.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Triferic AVNU Infusion Via Freedom Pump During Hemodialysis
Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)
Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.
A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients
Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Worked on TRIFERIC at Rockwell Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
TRIFERIC offers career stability in a mature, peak-stage product with entrenched market position but limited growth upside. The approaching 3-year LOE window makes this a strategic assignment for professionals focused on competitive defense, formulary management, and commercial optimization rather than launch dynamics.